The Ephrin Type A Receptor 2 pipeline drugs market research report outlays comprehensive information on the Ephrin Type A Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ephrin Type A Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Solid Tumor, and Glioblastoma Multiforme (GBM). It also reviews key players involved in Ephrin Type A Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Ephrin Type A Receptor 2 pipeline targets constitutes close to 33 molecules. Out of which, approximately 24 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 1, 12, and 4 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 1, 4, 3, and 1 molecule.
Ephrin Type A Receptor 2 overview
Ephrin Type A Receptor 2 (EPHA2) acts as a receptor for hepatitis C virus (HCV) in hepatocytes and human cytomegalovirus (HCMV) to mediate viral entry and fusion in glioblastoma cells. It binds promiscuously membrane-bound ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.
For a complete picture of Ephrin Type A Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
